Deutsches Rheuma-Forschungszentrum Berlin, A Leibniz Institute, Berlin, Germany.
Cell Harvesting Core, Berlin Institute of Health, Berlin, Germany.
EBioMedicine. 2023 Sep;95:104735. doi: 10.1016/j.ebiom.2023.104735. Epub 2023 Aug 8.
SARS-CoV-2 specific antibody-secreting plasma cells (PC) mediating specific humoral immunity have been identified in the human bone marrow (BM) after COVID-19 or vaccination against SARS-CoV-2. However, it remained unclear whether or not they acquire phenotypes of human memory plasma cells.
SARS-CoV-2-specific human bone marrow plasma cells (BMPC) were characterised by tetramer-based, antigen-specific flow cytometry and FluoroSpot assay.
SARS-CoV-2 spike-S1-specific PC were detectable in all tested BM samples of previously vaccinated individuals, representing 0.22% of total BMPC. The majority of SARS-CoV-2-specific BMPC expressed IgG and their specificity for the spike S1 protein indicated emergence from a systemic vaccination response. Of note, one-fifth of SARS-CoV-2-specific BMPC showed the phenotype of memory plasma cells, i.e., downregulated CD19 and present or absent CD45 expression.
Our data indicate the establishment of phenotypically diverse SARS-CoV-2-specific PC in the human BM after basic mRNA immunization, including the formation of memory phenotypes. These results suggest the induction of durable humoral immunity after basic mRNA vaccination against SARS-CoV-2.
The study was supported by funding by the DFG grants TRR130 TP24, ME 3644/8-1, and the Berlin Senate. SR received funding from DFGSFB-1444 C01 Central Service Project.
在 COVID-19 或接种 SARS-CoV-2 疫苗后，已在人类骨髓（BM）中鉴定出介导特异性体液免疫的 SARS-CoV-2 特异性抗体分泌浆细胞（PC）。然而，尚不清楚它们是否获得人类记忆浆细胞的表型。
通过基于四聚体的抗原特异性流式细胞术和 FluoroSpot 测定法对 SARS-CoV-2 特异性人骨髓浆细胞（BMPC）进行了表征。
在所有先前接种过疫苗的个体的测试 BM 样本中均检测到 SARS-CoV-2 刺突 S1 特异性 PC，占总 BMPC 的 0.22%。大多数 SARS-CoV-2 特异性 BMPC 表达 IgG，其对刺突 S1 蛋白的特异性表明其来自全身性疫苗接种反应。值得注意的是，五分之一的 SARS-CoV-2 特异性 BMPC 表现出记忆浆细胞的表型，即下调 CD19 并表达或不表达 CD45。
我们的数据表明，在基本 mRNA 免疫后，人类 BM 中建立了表型多样化的 SARS-CoV-2 特异性 PC，包括记忆表型的形成。这些结果表明，基本 mRNA 接种 SARS-CoV-2 可诱导持久的体液免疫。
该研究得到了德国研究基金会（DFG）授予的 TRR130 TP24、ME 3644/8-1 和柏林参议院的资助。SR 从 DFG SFB-1444 C01 中央服务项目获得了资助。
